

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant:** Noujaim  
**Serial No.:** 09/779,439  
**Filed:** February 8, 2001  
**Entitled:** METHOD FOR DIAGNOSING EFFICACY OF  
XENOTYPIC ANTIBODY THERAPY  
**Examiner:** L. Helms  
**Group Art Unit:** 1642  
**Attorney Docket:** ALT-006US1 (1009/007)

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED  
MAR 06 2003  
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

Claims 1-25 are pending in this application, and stand subject to a Restriction Requirement mailed April 25, 2002. A Petition for One-Month Extension of time up to and including June 25, 2002 along with the requisite fee is enclosed.

Applicants elect Claims 22-25, drawn to a method of diagnosing the efficacy of antibody mediated immunotherapy by measuring the level of a T cell response, classified in class 435, subclass 7.1.

If there are any questions, please contact the undersigned at the telephone number indicated below.


Date:

6/21/02

Respectfully submitted,

*W. A. Keown*

Wayne A. Keown, Ph.D.  
Reg. No. 33,923  
500 West Cummings Park  
Suite 2900  
Woburn, MA 01801  
781-938-1805 (Telephone)  
781-938-4777 (Facsimile)



Amdt A/#14  
J 3.14/03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Antoine Noujaim

Serial No: 09/779,439

Filed: February 8, 2001

For: METHOD FOR DIAGNOSING  
EFFICACY OF XENOTYPIC  
ANTIBODY THERAPY

Attorney Docket No. AREX-P01-006

Art Unit: 1642

Examiner: L.R. Helms

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

February 7, 2003

Date of Signature  
and of Mail Deposit

*Andrea Berlo*  
Andrea Berlo

Commissioner for Patents  
Washington, D.C. 20231

**REPLY UNDER 37 CFR 1.111**

Sir:

This amendment is being filed in reply to the outstanding non-final Office Action, mailed September 11, 2002, in connection with the above application.

Please enter the following amendments:

**In the claims:**

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

- Sub B1  
A1
22. (Amended) A method for diagnosing the efficacy of a xenotypic antibody-mediated immunotherapy comprising measuring the level of a T cell response produced by a patient that has a disease associated with an antigen to which the antibody binds, wherein the T cell response produced to such antigen after administration of the xenotypic antibody to the patient relative to the level of the